Media coverage about pSivida (NASDAQ:PSDV) has trended somewhat positive on Sunday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. pSivida earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.2789315696695 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
PSDV has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of pSivida in a research report on Wednesday, November 8th. Laidlaw initiated coverage on shares of pSivida in a research report on Wednesday, November 8th. They set a “buy” rating and a $5.00 target price on the stock. B. Riley set a $5.00 target price on shares of pSivida and gave the company a “buy” rating in a research report on Monday, December 4th. Finally, ValuEngine cut shares of pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. pSivida presently has an average rating of “Buy” and a consensus target price of $7.57.
Shares of pSivida (NASDAQ PSDV) traded down $0.04 during midday trading on Friday, hitting $1.23. 458,165 shares of the stock traded hands, compared to its average volume of 506,522. pSivida has a 52-week low of $1.03 and a 52-week high of $2.45.
pSivida (NASDAQ:PSDV) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.15). pSivida had a negative net margin of 226.31% and a negative return on equity of 139.56%. The company had revenue of $0.39 million for the quarter, compared to analyst estimates of $0.74 million. sell-side analysts anticipate that pSivida will post -0.58 earnings per share for the current fiscal year.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.